Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT ID: NCT04728893

This clinical trial is studying a new medication called nemtabrutinib (MK-1026) to see how safe and effective it is for people with certain blood cancers, including chronic lymphocytic leukemia (CL...

Recruiting

Phase: PHASE2 Conditions: Hematologic Malignancies, Non-Hodgkins Lymphoma +2 more

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT ID: NCT06074588

This clinical trial is studying a new treatment called sacituzumab tirumotecan for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific genetic changes, such as...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer (NSCLC)

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT ID: NCT06079879

This clinical trial is studying a new medication called bomedemstat (also known as MK-3543) to see if it works better than the best available treatments for people with essential thrombocythemia (E...

Recruiting

Phase: PHASE3 Conditions: Essential Thrombocythemia

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT ID: NCT06132958

This clinical trial is studying a new treatment called MK-2870, also known as sacituzumab tirumotecan, for women with endometrial cancer who have already received certain types of treatments. These...

Recruiting

Phase: PHASE3 Conditions: Endometrial Cancer

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT ID: NCT06170788

This clinical trial is studying a new treatment approach for patients with metastatic non-small cell lung cancer (NSCLC), specifically those whose tumors have a high level of a protein called PD-L1...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer (NSCLC)

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT ID: NCT06305754

This clinical trial is studying a new treatment called sacituzumab tirumotecan to see how it compares to a standard combination of two existing drugs, pemetrexed and carboplatin, for patients with ...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer (NSCLC)

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT ID: NCT06596694

This clinical trial is studying a new treatment called patritumab deruxtecan for people with advanced gastrointestinal (GI) cancers. Specifically, it focuses on cancers that have spread to other pa...

Recruiting

Phase: PHASE1 Conditions: Gastrointestinal Cancer

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT ID: NCT03519945

The LUCENT 3 clinical trial is studying a medication called mirikizumab to see how effective and safe it is for treating people with moderately to severely active ulcerative colitis (UC) over a lon...

Recruiting

Phase: PHASE3 Conditions: Ulcerative Colitis

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT ID: NCT05319730

This clinical trial is investigating new treatment options for patients with advanced esophageal squamous cell carcinoma, a type of cancer in the esophagus. It is focused on individuals who have al...

Recruiting

Phase: PHASE1 Conditions: Esophageal Squamous Cell Carcinoma

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT ID: NCT05843643

This clinical trial is studying the safety and effectiveness of a medication called upadacitinib for adults with moderate to severe systemic lupus erythematosus (SLE), a disease that causes inflamm...

Recruiting

Phase: PHASE3 Conditions: Systemic Lupus Erythematosus

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT ID: NCT06003426

This clinical trial is looking at a new medication called BMS-986278 to see how well it works, how safe it is, and how well people can tolerate it in those suffering from Idiopathic Pulmonary Fibro...

Recruiting

Phase: PHASE3 Conditions: Idiopathic Pulmonary Fibrosis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT ID: NCT06972459

This clinical trial is studying a medication called orforglipron to see how well it helps people with obesity or overweight lose weight, especially those who have at least one other related health ...

Recruiting

Phase: PHASE3 Conditions: Obesity, Overweight

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT ID: NCT06972472

This clinical trial is studying a medication called orforglipron to see how well it helps people with obesity or overweight who also have type 2 diabetes manage their blood sugar levels. Participan...

Recruiting

Phase: PHASE3 Conditions: Obesity, Type 2 Diabetes +1 more

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT ID: NCT07043400

This clinical trial is studying a cancer treatment called tislelizumab for adults with advanced stomach cancer or cancer where the stomach meets the esophagus. The goal is to compare two ways of gi...

Not yet recruiting

Phase: PHASE3 Conditions: Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT ID: NCT06018337

This clinical trial, called DYNASTY-Breast02, is looking at a new treatment option for patients with a specific type of metastatic breast cancer, which is cancer that has spread beyond the breast. ...

Recruiting

Phase: PHASE3 Conditions: Metastatic Breast Cancer

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT ID: NCT06052059

This clinical trial is studying a new medication called tulisokibart (MK-7240) to see if it is effective and safe for people with moderately to severely active ulcerative colitis, a condition that ...

Recruiting

Phase: PHASE3 Conditions: Ulcerative Colitis

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

NCT ID: NCT06376045

This clinical trial is studying a new medication called rocatinlimab to see how effective it is in reducing asthma flare-ups in adults with moderate to severe asthma. If you or a loved one have bee...

Recruiting

Phase: PHASE2 Conditions: Asthma

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT ID: NCT06430801

This clinical trial is studying a new medication called tulisokibart, which is being tested for its effectiveness and safety in treating people with moderate to severe Crohn's disease. Crohn's dise...

Recruiting

Phase: PHASE3 Conditions: Crohn's Disease

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT ID: NCT06136559

This clinical trial is studying a new medication called nemtabrutinib (MK-1026) to see how it compares to two existing treatments, ibrutinib and acalabrutinib, for patients with chronic lymphocytic...

Recruiting

Phase: PHASE3 Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

NCT ID: NCT06161116

This clinical trial is studying a new treatment called MK-6194 for adults with Systemic Lupus Erythematosus (SLE), a condition where the immune system mistakenly attacks healthy tissues. The main g...

Recruiting

Phase: PHASE2 Conditions: Systemic Lupus Erythematosus

Main Menu

Clinical Trials in Hefei, Anhui

425 Active Trials Found in Hefei

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)